Allele Biotech developed reprogramming mRNA cocktails are highly optimized in a multitude of ways including compatibility with modified or unmodified nucleotides, further integration of key engineered reprogramming factors, thoroughly tested capping structures, and reliable poly(A) tail addition methods. Several patents have been granted on the compositions and processes of Allele mRNA reprogramming in all major jurisdictions. Reprogramming technology has been licensed by or partnered with industry leaders in the iPSC field such Astellas, SCM Lifesciences, and Cellular Dynamics. It has also been partnered with California Institute of Regenerative Medicine (CIRM) grantees.
Licensing our groundbreaking mRNA-based reprogramming technology opens up a world of possibilities tailored to your specific needs. Through licensing, you gain access to our (1) large collection of off-the-shelf cGMP iPSC library, as well as (2) CDMO service to customize iPSC lines, and alternatively, (3) establishing your own reprogramming workflow based on our well-established procedures.
Whether you find yourself in an academic discovery stage, navigating the exciting terrain of a pre-seed-funded initiative, leading a well-funded startup venture, or even representing a medium to large biotech or pharmaceutical entity, our licensing approach is driven by adaptability and transparency. We understand that each journey in the realm of biotechnology is unique, and that’s why we empower you to choose from flexible licensing options (e.g. technology, iPSC line, licensing together with CDMO contract projects) that can align seamlessly with your aspirations and strategic goals. Your path to innovation is yours to shape, and we are here to provide the tools and resources to help you succeed.
To learn more about what licensing terms lines suit you the best, please contact us via email at email@example.com.
By leveraging the power of mRNA technology, we have effectively developed numerous iPSC differentiation protocols. To name a few: for in vitro functionally mature cells (without need to wait for post-implantation maturation), we can produce pancreatic β cells, lung epithelial cells, and hepatic cells; for highly proliferative lineage-committed precursors, we can produce myogenic precursor cells, neural progenitor cells, and oligodendrocyte precursors. These are just a few examples in addition to over two dozen differentiation protocols that have been developed.
If you encounter challenges related to the efficiency or consistency of your differentiation protocol, or if you are contemplating the launch of an iPSC-based cell therapy program, we encourage you to contact us via email at firstname.lastname@example.org. We may have a ready-to-implement solution that suits your needs.
We offer a range of licensing options tailored to meet your unique needs, ensuring that you can access and implement our cutting-edge technologies with ease. Our licensing process is designed with simplicity and flexibility at its core to streamline your path to innovation.